OraSure Technologies and Roche Diagnostics Sign Worldwide Commercialization Agreement for Fully Automated Oral Fluid Drugs of Abuse Assays

OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche Diagnostics announced that the companies have signed an agreement for the worldwide commercialization of homogeneous fully automated oral fluid drugs of abuse assays with OraSure's Intercept® oral specimen collection device. The oral fluid assays use Roche's KIMS (kinetic interaction of micro-particles in solution) technology and are being jointly developed under an agreement previously signed by the parties. The oral fluid assays are designed to run on various clinical chemistry automated analyzers, which is intended to allow oral fluid samples to be processed with the same efficiency as current fully automated urine-based drug...

Want to see the full article?

• Purchase this article for only $3.00